As the presidential race heats up, health care executives say they have many reasons to be excited--and nervous. BCG reviews an industry-wide survey on the implications of the candidates' health care proposals for the pharma and device industries.
by Pete Lawyer, Jon Kaplan, David Matheson, and Roger Sawhney, MD
Senators John McCain and Barack Obama are both touting big plans for health care reform. Those proposals may play well...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
